Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of BIIB059 in systemic lupus erythematosus with active cutaneous manifestations
MOH_2017-08-30_000245Phase 2Not yet recruiting
- Sponsor
- Biogen
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) comparing BIIB059 450 mg with Placebo (2 arms). Primary endpoint: Reduction in cutaneous disease activity. Planned start Jul 2017; status: not yet recruiting.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on MOH_2017-08-30_000245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-30_000245.